OR WAIT null SECS
November 02, 2018
Demand for highly potent APIs continues to rise.
October 30, 2018
The companies announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).
Mylan announced the launch of its biosimilar to AbbVie’s Humira across major European markets.
October 23, 2018
An advanced combination polymer for enteric coatings has been launched by Evonik and will be showcased during AAPS PharmSci 360 in Washington D.C.
October 17, 2018
Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy.
October 15, 2018
Clovis Oncology and Lonza celebrated the grand opening of a dedicated production train at Lonza’s Visp, Switzerland site for manufacturing Rubraca (rucaparib).
The company’s planned investment in its alkoxylation facility in the United States Gulf Coast will also expand production capacity for its polyethylene glycols.
The company was awarded for excellence in innovation for Parteck MXP Excipient and modified amino acids.
October 12, 2018
A new investigational vaccine, LASSARAB, shows promise for use against Lassa fever and rabies.
October 09, 2018
Audits by independent experts promise to ease the burden that customer audits can have on suppliers, while ensuring drug manufacturers that ingredients meet strict cGMP standards.